Compare Stocks: VIRI, CING, NMRA, and NTRB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CING Cingulate	$4.98 -4.0%	$5.03	$3.16 ▼ $11.89	$72.42M	-0.88	118,009 shs	76,662 shs
NMRA Neumora Therapeutics	$0.37 -5.4%	$0.79	$0.32 ▼ $3.65	$69M	2.95	1.92 million shs	1.11 million shs
NTRB Nutriband	$6.30 -5.1%	$6.36	$2.80 ▼ $9.19	$76.58M	1.92	37,135 shs	22,233 shs
VIRI Virios Therapeutics	$1.28 +4.1%	$1.70	$0.13 ▼ $1.04	$24.65M	1.58	1.05 million shs	62,216 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CING Cingulate	0.00%	0.00%	+4.84%	+3.97%	+39.89%
NMRA Neumora Therapeutics	0.00%	-3.22%	-33.24%	-77.19%	-85.31%
NTRB Nutriband	0.00%	+9.38%	-14.40%	+121.05%	-9.09%
VIRI Virios Therapeutics	+4.07%	+14.29%	-5.19%	-21.95%	-79.62%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CING Cingulate	$4.98 -4.0%	$5.03	$3.16 ▼ $11.89	$72.42M	-0.88	118,009 shs	76,662 shs
NMRA Neumora Therapeutics	$0.37 -5.4%	$0.79	$0.32 ▼ $3.65	$69M	2.95	1.92 million shs	1.11 million shs
NTRB Nutriband	$6.30 -5.1%	$6.36	$2.80 ▼ $9.19	$76.58M	1.92	37,135 shs	22,233 shs
VIRI Virios Therapeutics	$1.28 +4.1%	$1.70	$0.13 ▼ $1.04	$24.65M	1.58	1.05 million shs	62,216 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CING Cingulate	0.00%	0.00%	+4.84%	+3.97%	+39.89%
NMRA Neumora Therapeutics	0.00%	-3.22%	-33.24%	-77.19%	-85.31%
NTRB Nutriband	0.00%	+9.38%	-14.40%	+121.05%	-9.09%
VIRI Virios Therapeutics	+4.07%	+14.29%	-5.19%	-21.95%	-79.62%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CING Cingulate	2.50	Moderate Buy	$27.00	442.17% Upside
NMRA Neumora Therapeutics	2.78	Moderate Buy	$6.57	1,689.60% Upside
NTRB Nutriband	1.50	Reduce	N/A	N/A
VIRI Virios Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest VIRI, CING, NMRA, and NTRB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/20/2026	CING Cingulate	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
10/2/2026	CING Cingulate	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
9/28/2026	NTRB Nutriband	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/25/2026	NMRA Neumora Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
9/16/2026	CING Cingulate	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
8/23/2026	CING Cingulate	Roth Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target	Buy	$10.00 ➝ $9.00
8/18/2026	CING Cingulate	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
8/14/2026	NMRA Neumora Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 11/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CING Cingulate	N/A	N/A	N/A	N/A	$0.31 per share	N/A
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	$0.62 per share	N/A
NTRB Nutriband	$2.04M	37.55	N/A	N/A	$0.55 per share	11.45
VIRI Virios Therapeutics	N/A	N/A	N/A	N/A	$0.20 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CING Cingulate	-$22.45M	-$3.59	N/A	N/A	N/A	N/A	-238.40%	-128.67%	11/12/2026 (Estimated)
NMRA Neumora Therapeutics	-$236.93M	-$1.23	N/A	N/A	N/A	N/A	-242.28%	-131.32%	11/5/2026 (Estimated)
NTRB Nutriband	-$8.23M	-$0.53	N/A	N/A	N/A	-430.35%	-109.07%	-95.54%	12/7/2026 (Estimated)
VIRI Virios Therapeutics	-$5.30M	-$0.27	N/A	N/A	N/A	N/A	-130.33%	-115.00%	N/A

Latest VIRI, CING, NMRA, and NTRB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/12/2026	Q3 2026	CING Cingulate	-$0.48	N/A	N/A	N/A	$0.54 million	N/A
11/5/2026	Q3 2026	NMRA Neumora Therapeutics	-$0.19	N/A	N/A	N/A	N/A	N/A
9/4/2026	Q2 2027	NTRB Nutriband	N/A	-$0.07	N/A	-$0.07	N/A	$0.44 million
8/14/2026	Q2 2026	NMRA Neumora Therapeutics	-$0.2401	-$0.23	+$0.0101	-$0.23	N/A	N/A
8/13/2026	Q2 2026	CING Cingulate	-$0.63	-$0.45	+$0.18	-$0.45	$0.17 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CING Cingulate	N/A	N/A	N/A	N/A	N/A
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	N/A
NTRB Nutriband	N/A	N/A	N/A	N/A	N/A
VIRI Virios Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CING Cingulate	N/A	3.50	3.50
NMRA Neumora Therapeutics	1.19	4.50	4.50
NTRB Nutriband	N/A	4.21	4.02
VIRI Virios Therapeutics	N/A	7.27	7.27

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CING Cingulate	41.31%
NMRA Neumora Therapeutics	47.65%
NTRB Nutriband	19.70%
VIRI Virios Therapeutics	9.05%

Insider Ownership

Company	Insider Ownership
CING Cingulate	5.30%
NMRA Neumora Therapeutics	26.94%
NTRB Nutriband	52.21%
VIRI Virios Therapeutics	12.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CING Cingulate	14	14.54 million	13.77 million	Optionable
NMRA Neumora Therapeutics	63	187.90 million	137.28 million	Optionable
NTRB Nutriband	3	12.16 million	5.81 million	Not Optionable
VIRI Virios Therapeutics	5	19.26 million	16.91 million	No Data

VIRI, CING, NMRA, and NTRB Headlines

Recent News About These Companies

Die Virios-Therapeutics-Aktie bleibt ein spekulativer Nebenwert im Biotech-Segment

September 5, 2026 | ad-hoc-news.deA

Digital acceptance and commitment therapy for fibromyalgia – Authors' reply

June 13, 2025 | thelancet.comT

Dogwood Therapeutics Inc (DWTX)

March 16, 2025 | investing.com

Dogwood prices 578,950 shares at $8.26 in registered direct offering

March 13, 2025 | markets.businessinsider.com

Dogwood announces conversion of existing $19.5M in debt to equity

March 12, 2025 | markets.businessinsider.com

DWTX Stock trading resumes

February 11, 2025 | markets.businessinsider.com

Dogwood Therapeutics, Inc. (DWTX)

February 2, 2025 | finance.yahoo.com

DWTX Stock trading halted, volatility trading pause

January 28, 2025 | markets.businessinsider.com

DWTX Stock Hits 52-Week High at $15.74 Amidst Strong Yearly Growth

January 23, 2025 | msn.com

Dogwood announces first patient dosed in Phase 2b trial on Halneuron

January 21, 2025 | markets.businessinsider.com

Polluted communities hold their breath as companies struggle with California’s diesel truck ban

December 10, 2024 | apnews.comA

Dogwood Therapeutics faces potential Nasdaq delisting

November 23, 2024 | uk.investing.com

Dogwood says low-dose IMC-2 treatment reduces long-COVID fatigue

November 18, 2024 | markets.businessinsider.com

Dogwood Study Finds IMC-2 Treatment Reduces Long-COVID Related Fatigue, Sleep Disturbance

November 18, 2024 | markets.businessinsider.com

Inovio Pharmaceuticals (NASDAQ:INO) Stock Quotes, Forecast and News Summary

November 16, 2024 | benzinga.com

DWTX: Phase 2 Long COVID Results Expected Soon

November 12, 2024 | msn.com

Buy Rating for Dogwood Therapeutics: Strategic Initiatives and Promising Pipeline Drive Analyst Confidence

November 10, 2024 | markets.businessinsider.com

Dogwood Therapeutics Reports Q3 2024 Financial Results

November 9, 2024 | markets.businessinsider.com

Dogwood Therapeutics Announces Third Quarter 2024 Financial Results

November 8, 2024 | markets.businessinsider.com

Dogwood Therapeutics, Inc.: Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

October 31, 2024 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

VIRI, CING, NMRA, and NTRB Company Descriptions

Cingulate NASDAQ:CING

$4.98 -0.21 (-4.05%)

Closing price 10/30/2026 04:00 PM Eastern

Extended Trading

$5.12 +0.14 (+2.71%)

As of 10/30/2026 07:30 PM Eastern

Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Neumora Therapeutics NASDAQ:NMRA

$0.37 -0.02 (-5.43%)

Closing price 10/30/2026 04:00 PM Eastern

Extended Trading

$0.37 +0.00 (+1.03%)

As of 10/30/2026 07:56 PM Eastern

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Nutriband NASDAQ:NTRB

$6.30 -0.34 (-5.12%)

Closing price 10/30/2026 04:00 PM Eastern

Extended Trading

$6.32 +0.02 (+0.24%)

As of 10/30/2026 07:30 PM Eastern

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

Virios Therapeutics NASDAQ:VIRI

$1.28 +0.05 (+4.07%)

As of 10/30/2026

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VIRI, CING, NMRA, and NTRB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VIRI, CING, NMRA, and NTRB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VIRI, CING, NMRA, and NTRB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

VIRI, CING, NMRA, and NTRB Company Descriptions

Cingulate NASDAQ:CING

Neumora Therapeutics NASDAQ:NMRA

Nutriband NASDAQ:NTRB

Virios Therapeutics NASDAQ:VIRI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VIRI, CING, NMRA, and NTRB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VIRI, CING, NMRA, and NTRB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VIRI, CING, NMRA, and NTRB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

VIRI, CING, NMRA, and NTRB Company Descriptions

Cingulate NASDAQ:CING

Neumora Therapeutics NASDAQ:NMRA

Nutriband NASDAQ:NTRB

Virios Therapeutics NASDAQ:VIRI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools